| AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma |
NCT04631575: An Investigational Study of SHR6390 in Participants With Mild to Moderate Liver Impairment and Healthy Participants |
|
|
| Not yet recruiting | 1 | 24 | NA | SHR6390 | Jiangsu HengRui Medicine Co., Ltd. | Hepatic Impairment, Healthy Participants | 03/21 | 03/21 | | |
NCT04989829: Effect of Omeprazole on the Pharmacokinetics of SHR6390 in Healthy Subjects |
|
|
| Completed | 1 | 20 | RoW | SHR6390、Omeprazole | Jiangsu HengRui Medicine Co., Ltd. | Advanced Solid Tumor | 01/22 | 02/22 | | |
NCT05103826: A Study of SHR6390 Combined With Famitinib in the Treatment of ER + / HER2- Advanced Breast Cancer |
|
|
| Terminated | 1 | 3 | RoW | SHR6390、Famitinib | Jiangsu HengRui Medicine Co., Ltd. | ER+ / HER2- Advanced Breast Cancer | 06/23 | 06/23 | | |
NCT05515289: Study of SHR6390 in Renal Insufficiency and Healthy Subjects |
|
|
| Recruiting | 1 | 30 | RoW | SHR6390, dalpiciclib | Jiangsu HengRui Medicine Co., Ltd. | Breast Cancer | 08/23 | 09/23 | | |
NCT06225921: Neoadjuvant Adebrelimab With Dalpiciclib for Resectable Esophageal Squamous Cell Carcinomas |
|
|
| Recruiting | 1 | 6 | RoW | Adebrelimab, Dalpiciclib 100mg, Dalpiciclib 150mg | West China Hospital | Esophageal Squamous Cell Carcinoma | 01/25 | 01/25 | | |
NCT05189717: A Trial of HRS-8080 Tablets in Metastatic or Local Advanced Breast Cancer of Adults |
|
|
| Enrolling by invitation | 1 | 156 | RoW | HRS-8080 tablets、SHR 6390 tablets、Abemaciclib、Everolimus | Shandong Suncadia Medicine Co., Ltd. | Metastatic or Local Advanced Breast Cancer of Patients | 10/24 | 07/25 | | |
NCT06109207: Neoadjuvant Camrelizumab With Dalpiciclib for Resectable Esophageal or Head and Neck Squamous Cell Carcinomas |
|
|
| Recruiting | 1 | 12 | RoW | Camrelizumab, Dalpiciclib 100mg, Dalpiciclib 150mg | West China Hospital | Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma | 10/24 | 10/25 | | |
NCT05586841: Exploration of Dalpiciclib + Chidamide in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor: a Phase Ⅰb Study |
|
|
| Not yet recruiting | 1 | 30 | RoW | Dalpiciclib, SHR6390, Chidamide | Beijing 302 Hospital | HR+/HER2- Advanced Breast Cancer | 11/24 | 11/25 | | |
NCT04993430: A Phase 1 Study of HRS8807 Monotherapy and in Combination With SHR6390 in Subjects With ER-Positive, HER2-Negative Metastatic or Locally Advanced Breast Cancer |
|
|
| Recruiting | 1 | 90 | RoW | HRS8807, HRS8807、SHR6390 | Shanghai Hengrui Pharmaceutical Co., Ltd. | ER-Positive, HER2-Negative Breast Cancer | 12/24 | 12/24 | | |
ChiCTR2300075156: Phase I clinical study on tolerability, safety, and efficacy of Dalpiciclib combined with Apatinib in the treatment of patients with advanced or metastatic sarcoma |
|
|
| Not yet recruiting | 1 | 9 | | Dalpiciclib 100mg once daily oral d1-21+Apatinib 250mg once daily oral d1-28, every 28 days as one cycle; ;Dalpiciclib 100mg once daily oral d1-21+Apatinib 500mg once daily oral d1-28, every 28 days as one cycle; ;Dalpiciclib 150mg once daily oral d1-21+Apatinib 500mg once daily oral d1-28, every 28 days as one cycle; | Peking University Third Hospital; Peking University Third Hospital, Self-fding | Sarcoma | | | | |
NCT06099990: Dalpiciclib Isethionate Tablets Combined With Abiraterone Acetate Tablets (I) and Prednisone Tablets (AA-P) Versus Placebo Combined With AA-P in Treatment of High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC) |
|
|
| Not yet recruiting | 1 | 660 | NA | dalpiciclib isethionate tablets; abiraterone acetate tablets; prednisone tablets, placebo; abiraterone acetate tablets; prednisone tablets | Jiangsu HengRui Medicine Co., Ltd. | High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC) | 12/28 | 12/28 | | |
